Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-123-8 | CAS number: 10543-57-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
TAED was assessed for its potential to
induce gene mutations in a bacterial reverse mutation assay (Timm, 1988)
according to OECD Guideline 471 and GLP. The test was performed using
the plate incorporation method. The Salmonella typhimurium strains TA
1535, TA 1537, TA 1538, TA 98 and TA 100 and in addition the Escherichia
coli strain WP2 with and without S9-mix were examined applying test
concentrations of 10, 33.3, 100, 333.3 and 500 µg TAED/plate. 500 µg
TAED/plate was selected as the highest test concentration, since the
test substance was partially insoluble at this concentration. No
distinct toxic effects occurred in the test groups. Up to the highest
dose, no significant and reproducible increase in revertant colony
numbers was obtained in any of the strains used.
This result is supported by a further study performed according to the respective EPA OPPTS guideline (Insley, 1982). As this study was not done under GLP it represents supporting information. TAED was tested at concentrations of 10, 100, 1000 and 10000 µg/plate with and without S9-mix using Salmonella typhimurium strains TA 100, TA 1535, TA 98, TA 1537 and TA 1538. No indication was given whether TAED was soluble or remained undissolved at the various concentrations. The test substance did neither cause toxic effects nor an increase in revertant colony numbers in the Salmonella typhimurium strains used.
Chromosome Aberration Test in Vitro
The potential of TAED to induce structural chromosome aberrations was assessed in V79 cells of the Chinese hamster (Heidemann, 1989) and in human lymphocytes in vitro (Wright, 1995). Both studies were conducted according to the OECD Guideline 473 and GLP.
Duplicate human lymphocyte cultures
were treated with the test substance and evaluated for chromosome
aberrations, together with vehicle (PEG 400) and positive controls. Four
treatment conditions were used: 4 hours of exposure in the presence of
S9-mix with cell harvest 20 hours and 44 hours after start of treatment,
and a 20 and 44 hour continuous exposure in the absence of activation.
Two independent experiments were performed. In experiment 1 (20 hour
harvest) 570, 1140 and 2280 µg/mL (equivalent to 10 mM) were selected
for chromosomal analysis. In experiment 2, cultures were exposed to TAED
at 570, 1140 and 2280 µg/mL (20 hour harvest), or 2280 µg/mL (44 hour
harvest). There was no real evidence of toxicity of TAED at the 20 hour
harvest, but at the 44 hour harvest mean mitotic indices were reduced to
approximately 65% of the vehicle control value, both in the presence and
absence of S9 -mix. The solubility of TAED at the given concentrations
in the culture medium was not reported. Chromosomal analysis revealed
that TAED induced no biologically or reproducible, statistically
significant increases in the frequency of cells with aberrations.
Duplicate cultures of V79 cells were
treated with TAED for 4 hours in the presence and absence of S9-mix,
harvested at 7 hours, 18 hours and 28 hours after start of treatment and
evaluated for chromosome aberrations. Solvent and positive controls were
included in the study. TAED concentrations tested were 500 µg/mL in
cultures harvested after 7 or 28 hours and 20, 200 and 500 µg/mL in
cultures harvested after 18 hours. 500 µg/mL was chosen as the maximum
concentration, because higher concentrations could not be dissolved in
the culture medium. The mitotic index was only slightly reduced at 500
µg/mL at the 7 h harvest in the presence and absence of S9-mix. There
was no relevant increase in cells with structural aberrations.
TAED was non-clastogenic to V79 cells of the Chinese hamster and human
lymphocytes in vitro under the experimental conditions used.
Mammalian Cell Gene Mutation Test (HPRT test)
The test item TAED was assessed for its potential to induce gene mutations at the HPRT locus using V79 cells of the Chinese hamster according to OECD TG 476.
The study was performed in two independent experiments, using identical experimental procedures. In the first experiment the treatment period was 4 hours with and without metabolic activation. The second experiment was performed with a treatment time of 4 hours with and 24 hours without metabolic activation.
The main experiments were evaluated at the following concentrations (the maximum concentration of 2280.0 µg/mL is equal to approximately 10 mM):
exposure |
S9 |
concentrations |
||||
|
|
Experiment I |
||||
4 hours |
- |
71.3 |
142.5 |
285.0 |
570.0P |
1140.0P |
4 hours |
+ |
71.3 |
142.5 |
285.0 |
570.0P |
1140.0P |
|
|
Experiment II |
||||
24 hours |
- |
142.5 |
285.0 |
570.0 |
1140.0P |
2280.0P |
4 hours |
+ |
142.5 |
285.0 |
570.0 |
1140.0P |
2280.0P |
P precipitation of the test item visible at the end of treatment
Precipitation of the test item visible to the naked eye at the end of treatment was noted in experiment I at 570.0 µg/mL and above with and without metabolic activation. In experiment II precipitation occurred at 1140.0 µg/mL and above with and without metabolic activation.
There was no relevant cytotoxic effect indicated by a relative cloning efficiency I or cell density below 50% up to the maximum concentration with and without metabolic activation.
No relevant and reproducible increase in mutant colony numbers/106cells was observed in the main experiments up to the maximum concentration. The mutation frequency did not exceed the historical range of solvent controls.
A linear regression analysis (least squares) was performed to assess a possible dose dependent increase of mutant frequencies. No dose dependent trend of the mutation frequency indicated by a probability value of <0.05 was determined in any of the experimental parts.
In both experiments of this study (with and without S9 mix) the range of the solvent controls was from 5.1 up to 19.6 mutants per 106cells; the range of the groups treated with the test item was from 3.3 up to 25.5 mutants per 106cells.
EMS(150 µg/mL) and DMBA (1.1 µg/mL) were used as positive controls and showed a distinct increase in induced mutant colonies.
In conclusion it can be stated that under the experimental conditions reported the test item did not induce gene mutations at the HPRT locus in V79 cells. Therefore, TAED is considered to be non-mutagenic in this HPRT assay.
Micronucleus Test in Vivo
In a micronucleus test performed
according to OECD Guideline 474 and GLP (Durward, 1995), groups of 10
albino CD-1 mice (5 males and 5 females) were given a single oral dose
of TAED at 312.5, 625 and 1250 mg/kg bw. Negative and positive control
groups receiving the vehicle, arachis oil, or cyclophosphamide were also
included. Control and high dose animals were killed 24, 48 and 72 hours
after dosing; animals of intermediate and low dosage groups as well as
the positive control group were killed 24 hours after dosing. Bone
marrow was extracted from the femurs and smear preparations were made
and stained. Three premature deaths were observed after dosing with 1250
mg/kg bw. There were no statistically significant increases in the
frequency of micronucleated polychromatic erythrocytes in animals dosed
with TAED when compared to the concurrent vehicle control groups. No
significant change in the ratio of polychromatic/normochromatic
erythrocytes was observed, but the presence of clinical observations and
premature deaths at the high dose level indicated that systemic
absorption had occurred.
In conclusion, TAED was considered to be non-genotoxic in the
micronucleus test in vivo.
This conclusion is supported by the outcome of a further micronucleus test (Wallat, 1984). The test followed the principles of OECD Guideline 474, but is not in accordance with GLP and represents therefore supporting information. Groups of mice (7 males and 7 females) received TAED at dose levels of 250, 1250 and 2500 mg/kg bw given twice, separated by an interval of 24 hours, by oral gavage. Negative and positive control groups receiving the vehicle, carboxymethyl cellulose (1%)/cremophor (0.5%), or cyclophosphamide were also included. The animals were sacrificed 30 hours after the first substance application and bone marrow smears from both femurs were prepared. No premature deaths occurred. No significant change in the ratio of polychromatic/normochromatic erythrocytes was observed, but the presence of clinical observations indicated that systemic absorption had occurred. At all dose levels the group mean micronucleated cell count of TAED was comparable with the concurrent negative control value.
Justification for selection of genetic toxicity endpoint
Endpoint selection:
KEY_471/472_1988_CCR_89.0054,
KEY_473_1995_Safepharm_ProjectNo.167/063,
KEY_476_HPRT_2014_Harlan_1578800,
KEY_474_MN in vivo_1995_Safepharm_167/064
Short description of key information:
TAED was non-mutagenic in the bacterial reverse mutation assay using Salmonella typhimurium strains TA 1535, TA 1537, TA 1538, TA 98 and TA 100 and the Escherichia coli strain WP2 with and without S9-mix , non-castogenic in V79 cells and human lymphocyte cultures, did not induce gene mutations at the HPRT locus in V79 cells and was non-mutagenic in the in vivo micronucleus test in mice.
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
TAED was non-mutagenic in the bacterial reverse mutation assays and in the in vitro mammalian cell gene mutaion assay (HPRT), non-castogenic in V79 cells and human lymphocyte cultures and non-mutagenic in the micronucleus test in vivo. Based on these data it is concluded that TAED is not subject to classification and labelling according to Directive 67/548/EEC and Regulation 1272/2008/EC regarding genetic toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.